Want to see AVTX full AI Analyst Report?
Avalo Therapeutics (AVTX) Income Statement
Avalo Therapeutics Income Statement
Last quarter (Q2 2026), Avalo Therapeutics's total revenue was $0.00. In Q2, Avalo Therapeutics's net income was $-36.36M. See Avalo Therapeutics’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 59.00K | $ 441.00K | $ 1.92M | $ 18.05M | $ 5.40M | |
| $ 59.00K | $ 807.00K | $ 640.00K | $ 14.62M | $ 3.91M | |
| $ 72.98M | $ 69.32M | $ 27.99M | $ 52.06M | $ 86.04M | |
| Depreciation and Amortization | $ 344.00K | $ 169.00K | $ 158.00K | $ 166.00K | $ 1.66M |
| $ -77.75M | $ -34.85M | $ -23.29M | $ -37.29M | $ -80.50M | |
| $ -72.92M | $ -68.51M | $ -27.35M | $ -37.44M | $ -82.13M | |
| $ -5.17M | $ 33.50M | $ -4.18M | $ -4.19M | $ -2.41M | |
| $ -78.09M | $ -35.02M | $ -31.53M | $ -41.63M | $ -84.55M | |
| $ -78.26M | $ -35.13M | $ -31.54M | $ -41.66M | $ -84.38M | |
| Per Share Metrics | |||||
| Basic EPS | $ -5.84 | $ -4.32 | $ -113.58 | $ -1062.65 | $ -2330.66 |
| Diluted EPS | $ -5.84 | $ -3.26 | $ -113.58 | $ -1062.65 | $ -2330.66 |
| Weighted Average Shares Outstanding | 13.40M | 8.13M | 277.73K | 39.20K | 36.19K |
| Weighted Average Shares Outstanding (Diluted) | 13.40M | 10.78M | 277.73K | 39.20K | 36.19K |
Currency in USD
